Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vicore Pharma Holding AB ( (SE:VICO) ) has provided an announcement.
Vicore Pharma announced its participation in the DNB Carnegie Nordic Healthcare Conference in Oslo, where CFO Hans Jeppsson will present and engage in one-on-one meetings. This participation underscores Vicore’s active engagement with the healthcare investment community, potentially enhancing its visibility and fostering strategic partnerships.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), with potential applications in respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid, is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
Average Trading Volume: 677,464
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.33B
See more data about VICO stock on TipRanks’ Stock Analysis page.